Skip to content

Duration of ddI treatment and dose risk factors for CD4 loss in patients taking ddI/tenofovir

Once daily Kaletra: dose escalation rarely the answer for those with low plasma levels

Tenofovir may linger up to 3 weeks in body: discontinue with caution

Efavirenz and anti-convulsant drug phenytoin interact: TDM of value when used together

Increased risk of oral contraceptive failure with nelfinavir

Atazanavir interactions with tenofovir and Viagra included on new US labelling

Blood concentrations of indinavir too low when dosed with rifampicin even if ritonavir boosted

Warning on atazanavir and tenofovir combination

Garlic blocks HIV drugs